CRISPR/Cas9 gene editing: A new hope for transthyretin amyloidosis treatment
Ann Med Surg (Lond)
.
2022 Sep 28:83:104784.
doi: 10.1016/j.amsu.2022.104784.
eCollection 2022 Nov.
Authors
Faizan Shahzad
1
,
Mohammad Ebad Ur Rehman
1
,
Jawad Basit
1
,
Sajeel Saeed
2
,
Khawar Abbas
2
,
Muhammad Farhan
1
Affiliations
1
Department of Medicine, Rawalpindi Medical University, Block E Satellite Town, Rawalpindi, Pakistan.
2
Department of Surgery, Rawalpindi Medical University, Block E Satellite Town, Rawalpindi, Pakistan.
PMID:
36263082
PMCID:
PMC9574705
DOI:
10.1016/j.amsu.2022.104784
No abstract available
Keywords:
Amyloidosis; CRISPR; Gene editing.